<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26560218</article-id>
      <article-id pub-id-type="pmc">4631238</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153296</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Persistent docetaxel-induced supravenous erythematous eruption<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Fernandes</surname>
            <given-names>Karina de Almeida Pinto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Felix</surname>
            <given-names>Paulo Ant&#xF4;nio Oldani</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Hospital Naval Marc&#xED;lio Dias (HNMD) &#x2013; Rio de Janeiro (RJ),
Brazil.</aff>
      <aff id="aff02"><label>2</label>Hospital dos Servidores do Estado do Rio de Janeiro &#x2013; Rio
de Janeiro (RJ), Brazil.</aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Karina de Almeida Pinto Fernandes, Rua Cezar Zama,
185, Lins de Vasconcelos, 20725-090 - Rio de Janeiro, RJ, Brazil. E-mail:
<email>kfernandesugf@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>5</issue>
      <fpage>728</fpage>
      <lpage>730</lpage>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>12</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>2</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Taxanes are drugs used to treat many types of cancer, including breast and lung
cancer. The most common side effects of these drugs are neutropenia and mucositis.
Signs of skin toxicity are observed in about 65% of cases and include alopecia,
hypersensitivity reactions, persistent supravenous erythematous eruption, nail
changes, scleroderma reactions and others. We report two cases of skin reaction to
docetaxel and warn that it is not necessary to interrupt the treatment in these
cases.</p>
      </abstract>
      <kwd-group>
        <kwd>Drug eruptions</kwd>
        <kwd>Skin abnormalities</kwd>
        <kwd>Taxoids</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Taxanes, such as paclitaxel (<italic>Taxol<sup>&#xAE;</sup></italic>) and docetaxel
(<italic>Taxotere<sup>&#xAE;</sup></italic>) are drugs used in the treatment of several
tumors. Although there are no epidemiological studies on these drugs, cutaneous side
effects are frequent, with an estimated incidence of 65%. These reactions may alter the
quality of life of the patients, therefore relief for the symptoms and prevention of
reactions are essential.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> We report 2
cases of cutaneous reaction to docetaxel (DCX), with the objective of familiarizing
dermatologists with the side effects of chemotherapy with taxanes and advise them about
the conduct to be adopted.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Case 1: Female patient, 68 years old, diagnosed with breast carcinoma of the
infiltrating ductal type, grade 3, being treated with neoadjuvant chemotherapy. She
underwent 4 cycles with doxorubicin and cyclophosphamide and 4 cycles with docetaxel and
trastuzumab. The patient mentioned that few days after the second session of
chemotherapy with docetaxel and trastuzumab she presented an erythematous macule,
slightly pruriginous, on the left forearm. The clinical examination revealed a
supravenous brownish macule that followed the venous pathway on the left upper limb,
onycholysis on the fingers and alopecia (<xref ref-type="fig" rid="f01">Figure
1</xref>). In face of the clinical findings we concluded that it was a persistent
erythematous eruption that followed the venous pathway, secondary to use of DCX.
Methylpredisolone aceponate was prescribed once a day, for 7 days. The patient
progressed with residual hyperpigmentation (<xref ref-type="fig" rid="f02">Figure
2</xref>). Case 2: Female patient, 65 years old, diagnosed with breast carcinoma of
the infiltrating ductal type, grade 4, with metastasis to the lung, undergoing
palliative chemotherapy with DCX and filgrastim. She mentioned a pruriginous
erythematous macule that appeared on the left forearm a few days after the third cycle
of chemotherapy and hyperpigmentation of the nail plate after the sixth cycle. The
clinical examination revealed erythematous-brownish macules on the back of hand,
following the venous pathway on the left upper limb and chromonychia (<xref ref-type="fig" rid="f03">Figure 3</xref>). She was diagnosed with persistent
erythematous rash following the venous pathway secondary to use of DCX and treatment was
started with methylpredisolone aceponate once a day for 7 days, with complete remission
of lesion 3 months after the end of chemotherapy (<xref ref-type="fig" rid="f04">Figure
4</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Brownish macule following the venous pathway on the upper left limb</p>
        </caption>
        <graphic xlink:href="abd-90-05-0728-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Residual hyperpigmentation following venous pathway on the upper left limb</p>
        </caption>
        <graphic xlink:href="abd-90-05-0728-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Erythematous-brownish macules on back of hand following venous pathway on the
upper left limb</p>
        </caption>
        <graphic xlink:href="abd-90-05-0728-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Complete remission of lesion 3 months after the end of chemotherapy</p>
        </caption>
        <graphic xlink:href="abd-90-05-0728-g04"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>In Brazil there are two types of taxanes, paclitaxel and docetaxel. They present similar
action, but distinct side effects. These drugs act stabilizing the microtubules of
mitosis, preventing breakdown and leading to cell death.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> The antineoplastic drugs are classified according to the
aggressive potential of blood vessels and adjacent tissues. They may be irritating or
vesicant. The irritating drugs, such as fluorouracil, carmustine, docetaxel and
etopiside cause tissue damage that does not progress with necrosis. They my cause
erythema, pain, inflammation at the puncture site and venous pathway and a burning
sensation. The vesicant drugs, such as dactinomycin, doxorubicin, vincristine and
vinblastine, cause erythema, edema, vesicles and cutaneous necrosis with functional and
estethic damage.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> The skin, the mucous membranes and skin appendages are
tissues that have rapid cellular proliferation, therefore are very susceptible to
adverse reactions resulting from anticancer systemic treatment. Docetaxel may cause a
variety of side effects as alopecia, acral erythrodysesthesia, onycholysis,
hyperpigmentation of the nail plate, urticaria, angioedema and persistent erythematous
rash that follows the venous pathway<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup>. The persistent erythematous eruption
that follows the venous pathway, also known as serpiginous eruption, is characterized by
erythematous macules or erythematous-purpuric papules at the site of infusion of the
chemotherapeutic agent or along the venous pathway, which many times can progress with
residual hyperpigmentation. These lesions may appear between 24 hours and 15 days after
infusion of the cytotoxic drug and disappear spontaneously in weeks or months. Numerous
drugs may cause this reaction, including 5-fluorouracil, docetaxel, vinorelbine and
dacarbazine.<sup><xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup> The etiology is not well defined. It is believed that a
chemotherapeutic agent generates a direct cytotoxicity in the vascular endothelium,
increasing its permeability and contributing to the leakage of the medication out of the
vessel, producing a direct toxic effect on keratinocytes and melanocytes.<sup><xref rid="r06" ref-type="bibr">6</xref></sup> The histopathological findings of this
reaction are unspecific, characterized by vacuolar interface dermatitis. The presence of
spongiosis and occasional dyskeratotic cells have been reported. Prevention of this
eruption can be achieved through a saline infusion before and after
chemotherapy.<sup><xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup> In long chemotherapeutic sessions, lasting over one hour,
with vesicant drugs, peripheral venous access should be replaced by central
access.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Some articles defend
the use of oral corticosteroids before and after chemotherapy, with the objective of
suppressing the inflammatory response.<sup><xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup> An increased incidence of
cutaneous toxicity has been reported when docetaxel is infused rapidly, in a short
period of time.<sup><xref rid="r08" ref-type="bibr">8</xref></sup> The management of
this reaction includes immediate interruption of infusion and elevation of the affected
member. Application of cold compresses is beneficial due to venous constriction and more
intensive degradation of toxic metabolic substances, in addition to alleviating pain and
inflammation.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> The use of topical or systemic corticosteroids associated
with antihistamines has also been reported.<sup><xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup> In cases of leakage of
vesicant drugs some antidotes may be used.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup> It is important to
emphasize that the interruption of chemotherapy or modification of the standard dose of
the chemotherapeutic drug is not indicated in face of this reaction because it is
self-limited.<sup><xref rid="r06" ref-type="bibr">6</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of Interest: None.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Fernandes KAP, Felix PAO. Persistent
docetaxel-induced supravenous erythematous eruption. An Bras Dermatol.
2015;90(5):728-30.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Study carried out at the Hospital Naval Marc&#xED;lio Dias (HNMD) &#x2013; Rio de Janeiro (RJ),
Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Donati</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>LG</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous adverse reactions to chemotherapy with taxanes: the
dermatologist's point of view</article-title>
          <source>An Bras Dermatol</source>
          <year>2011</year>
          <volume>86</volume>
          <fpage>755</fpage>
          <lpage>758</lpage>
          <pub-id pub-id-type="pmid">21987144</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Criado</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Moure</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Sanches</surname>
              <given-names>JA</given-names>
              <suffix>J&#xFA;nior</suffix>
            </name>
          </person-group>
          <article-title>Adverse mucocutaneous reactions related to chemotherapeutic agents:
part II</article-title>
          <source>An Bras Dermatol</source>
          <year>2010</year>
          <volume>85</volume>
          <fpage>591</fpage>
          <lpage>608</lpage>
          <pub-id pub-id-type="pmid">21152783</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Susser</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Whitaker-Worth</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Grant-Kels</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Mucocutaneous reactions to chemotherapy</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1999</year>
          <volume>40</volume>
          <fpage>367</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="pmid">10071309</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanches</surname>
              <given-names>JA</given-names>
              <suffix>Junior</suffix>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Moure</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Criado</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>Adverse mucocutaneous reactions to chemotherapeutic agents: part
I</article-title>
          <source>An Bras Dermatol</source>
          <year>2010</year>
          <volume>85</volume>
          <fpage>425</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="pmid">20944902</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aydogan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kavak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Parlak</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Alper</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Annakkaya</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Erbas</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Persistent serpentine supravenous hyperpigmented eruption associated
whit docetaxel</article-title>
          <source>J Eur Acad Dermatol Venereol</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>345</fpage>
          <lpage>347</lpage>
          <pub-id pub-id-type="pmid">15857462</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mataix</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Betlloch</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Palmero</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Persistent supravenous eruption induced by intravenous bortezomib
therapy</article-title>
          <source>Br J Dermatol</source>
          <year>2008</year>
          <volume>158</volume>
          <fpage>863</fpage>
          <lpage>864</lpage>
          <pub-id pub-id-type="pmid">18284402</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cifuentes</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ring</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brockow</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Extravasation of docetaxel</article-title>
          <source>J Dtsch Dermatol Ges</source>
          <year>2012</year>
          <volume>10</volume>
          <fpage>662</fpage>
          <lpage>663</lpage>
          <pub-id pub-id-type="pmid">22734918</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chew</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chuen</surname>
              <given-names>VS</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous reaction associated with weekly docetaxel
administration</article-title>
          <source>J Oncol Pharm Pract</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>29</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="pmid">18753180</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ho</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>CY</given-names>
            </name>
          </person-group>
          <article-title>Vesicant-type reaction due to docetaxel extravasion</article-title>
          <source>Acta Derm Venereol</source>
          <year>2003</year>
          <volume>83</volume>
          <fpage>467</fpage>
          <lpage>468</lpage>
          <pub-id pub-id-type="pmid">14690348</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
